Bexarotene D4

Modify Date: 2025-08-23 17:33:40

Bexarotene D4 structure	Common Name	Bexarotene D4
	CAS Number	2182068-00-2	Molecular Weight	352.50
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₄H₂₄D₄O₂	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Bexarotene D4

Bexarotene D4 is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma[1][2][3][4][5].

Name	Bexarotene D4

Description	Bexarotene D4 is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma[1][2][3][4][5].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Metabolic Enzyme/Protease >> RAR/RXR
References	[1]. Vakeva L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol. 2012 May;92(3):258-63. doi: 10.2340/00015555-1359. [2]. Gui Y, et al. Bexarotent attenuated CCI-induced spinal neuroinflammation and neuropathic pain by targeting MKP-1. J Pain. 2019 Jan 17. pii: S1526-5900(18)30607-2. [3]. Zhang X, Schlaak M, Fabri M, Mauch C, Kurschat P. Successful Treatment of a Panniculitis-Like Primary Cutaneous T-Cell Lymphoma of the α/β Type with Bexarotene. Case Rep Dermatol. 2012 Jan;4(1):56-60. [4]. Orendas P, Kubatka P, Kajo K, Stollarova N, Kassayova M, Bojkova B, Pec M, Nosal V, Kiskova T, Zihlavnikova K, Karsnakova R. Melatonin enhanced bexarotene efficacy in experimental mammary carcinogenesis. Neoplasma. 2012;59(4):469-74. [5]. Cras A, Politis B, Balitrand N, Darsin-Bettinger D, Boelle PY, Cassinat B, Toubert ME, Chomienne C.

Description

Bexarotene D4 is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma[1][2][3][4][5].

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> Autophagy >> Autophagy

Signaling Pathways >> Metabolic Enzyme/Protease >> RAR/RXR

References

[1]. Vakeva L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol. 2012 May;92(3):258-63. doi: 10.2340/00015555-1359.

[2]. Gui Y, et al. Bexarotent attenuated CCI-induced spinal neuroinflammation and neuropathic pain by targeting MKP-1. J Pain. 2019 Jan 17. pii: S1526-5900(18)30607-2.

[3]. Zhang X, Schlaak M, Fabri M, Mauch C, Kurschat P. Successful Treatment of a Panniculitis-Like Primary Cutaneous T-Cell Lymphoma of the α/β Type with Bexarotene. Case Rep Dermatol. 2012 Jan;4(1):56-60.

[4]. Orendas P, Kubatka P, Kajo K, Stollarova N, Kassayova M, Bojkova B, Pec M, Nosal V, Kiskova T, Zihlavnikova K, Karsnakova R. Melatonin enhanced bexarotene efficacy in experimental mammary carcinogenesis. Neoplasma. 2012;59(4):469-74.

[5]. Cras A, Politis B, Balitrand N, Darsin-Bettinger D, Boelle PY, Cassinat B, Toubert ME, Chomienne C.

Molecular Formula	C₂₄H₂₄D₄O₂
Molecular Weight	352.50
InChIKey	NAVMQTYZDKMPEU-ULDPCNCHSA-N
SMILES	C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Bexarotene D4

Use of Bexarotene D4

Names

Bexarotene D4 Biological Activity

Chemical & Physical Properties

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.